Clark Estates Inc. NY Has $2.86 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Clark Estates Inc. NY reduced its stake in Halozyme Therapeutics by 27.6% in the first quarter, owning 44,868 shares after selling 17,132 shares during that period.
• CEO Helen Torley sold 20,000 shares of the company's stock, decreasing her position by 2.65%, with the transaction valued at over $1.1 million.
• Halozyme Therapeutics has shown strong financial performance, with a net margin of 44.76% and revenue growth of 35.2% year-over-year, reporting $1.11 EPS which exceeded analysts' expectations.

Clark Estates Inc. NY lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,868 shares of the biopharmaceutical company's stock after selling 17,132 shares during the period. Halozyme Therapeutics comprises approximately 0.6% of Clark Estates Inc. NY's portfolio, making the stock its 23rd biggest position. Clark Estates Inc. NY's holdings in Halozyme Therapeutics were worth $2,863,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $60,054,000. Capital World Investors acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $35,773,000. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 141.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after acquiring an additional 581,475 shares in the last quarter. D. E. Shaw & Co. Inc. grew its position in Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after acquiring an additional 524,802 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Halozyme Therapeutics during the fourth quarter worth $21,838,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 60,000 shares of company stock worth $3,262,400. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO traded down $0.95 during mid-day trading on Friday, reaching $59.02. The company had a trading volume of 1,675,654 shares, compared to its average volume of 1,284,478. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The company has a market capitalization of $7.27 billion, a P/E ratio of 15.70, a P/E/G ratio of 0.40 and a beta of 1.17. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.50. The company's 50-day moving average is $55.30 and its 200-day moving average is $57.70.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The firm's revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.79 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of analyst reports. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research report on Tuesday, May 13th. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Finally, HC Wainwright reissued a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $62.70.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.